S. Francesca Annan
Research Subjects
S. Francesca Annan has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Andrew J. McKay
Liverpool Clinical Trials Centre, University of Liverpool, a member of Liverpool Health Partners, Liverpool, UK
1 shared publication - Anne L. Peters
Keck School of Medicine, University of Southern California, Los Angeles, USA
1 shared publication - Cari Berget
Barbara Davis Center for Diabetes University of Colorado Aurora Colorado USA
1 shared publication - Carrol Gamble
Liverpool Clinical Trials Centre, University of Liverpool, Liverpool, UK
1 shared publication - Colin Ridyard
Centre for Health Economics and Medicines Evaluation, Bangor University, Bangor, UK
1 shared publication - Dorothee Deiss
Diabeteszentrum für Kinder und Jugendliche Westend, DRK Kliniken Berlin, Berlin, Deutschland
1 shared publication
Latest Publications
- 2 August 2026
- Published by Springer Nature
- p. 173-187
The Role of Technology in the Nutritional Management of Diabetes
- 2 August 2026
- Published by Springer Nature
- p. 173-187
The Role of Technology in the Nutritional Management of Diabetes
- 2 April 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 27 (6) , 2909-2919
Practical considerations for using the Omnipod® 5 Automated Insulin Delivery System: Clinical experience from the United States and Europe
Automated insulin delivery (AID) systems, which consist of an insulin pump, a continuous glucose monitoring system and a software algorithm to automate insulin delivery based on real time glycaemic data, are rapidly evolving. AID is now strongly recommended as the insulin delivery method of choice for people with type 1 diabetes. This article reviews the features and current multinational availability of the Omnipod® 5 Automated Insulin Delivery System and summarizes the latest evidence in support of its efficacy, safety and optimal use. It also provides a series of clinical vignettes illustrating advanced issues related to the initiation and ongoing optimization of insulin therapy using the system, including how to personalize settings and optimize glycaemic outcomes in a variety of clinical circumstances.
- 2 April 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 27 (6) , 2909-2919
Practical considerations for using the Omnipod® 5 Automated Insulin Delivery System: Clinical experience from the United States and Europe
Automated insulin delivery (AID) systems, which consist of an insulin pump, a continuous glucose monitoring system and a software algorithm to automate insulin delivery based on real time glycaemic data, are rapidly evolving. AID is now strongly recommended as the insulin delivery method of choice for people with type 1 diabetes. This article reviews the features and current multinational availability of the Omnipod® 5 Automated Insulin Delivery System and summarizes the latest evidence in support of its efficacy, safety and optimal use. It also provides a series of clinical vignettes illustrating advanced issues related to the initiation and ongoing optimization of insulin therapy using the system, including how to personalize settings and optimize glycaemic outcomes in a variety of clinical circumstances.
- Top Cited Papers
- 5 December 2022
- Published by Wiley in Pediatric Diabetes
- Vol. 23 (8) , 1297-1321
ISPAD Clinical Practice Consensus Guidelines 2022: Nutritional management in children and adolescents with diabetes
- 5 December 2022
- Published by Wiley in Pediatric Diabetes
- Vol. 23 (8) , 1297-1321
Top Cited PapersISPAD Clinical Practice Consensus Guidelines 2022: Nutritional management in children and adolescents with diabetes
- 1 August 2018
- Published by National Institute for Health and Care Research in Health Technology Assessment
- Vol. 22 (42) , 1-112
Continuous subcutaneous insulin infusion versus multiple daily injections in children and young people at diagnosis of type 1 diabetes: the SCIPI RCT
Background: The risk of developing long-term complications of type 1 diabetes (T1D) is related to glycaemic control and is reduced by the use of intensive insulin treatment regimens: multiple daily injections (MDI) (≥ 4) and continuous subcutaneous insulin infusion (CSII). Despite a lack of evidence that the more expensive treatment with CSII is superior to MDI, both treatments are used widely within the NHS. Objectives: (1) To compare glycaemic control during treatment with CSII and MDI and (2) to determine safety and cost-effectiveness of the treatment, and quality of life (QoL) of the patients. Design: A pragmatic, open-label randomised controlled trial with an internal pilot and 12-month follow-up with 1 : 1 web-based block randomisation stratified by age and centre. Setting: Fifteen diabetes clinics in hospitals in England and Wales. Participants: Patients aged 7 months to 15 years. Interventions: Continuous subsutaneous insulin infusion or MDI initiated within 14 days of diagnosis of T1D. Data sources: Data were collected at baseline and at 3, 6, 9 and 12 months using paper forms and were entered centrally. Data from glucometers and CSII were downloaded. The Health Utilities Index Mark 2 was completed at each visit and the Pediatric Quality of Life Inventory (PedsQL, diabetes module) was completed at 6 and 12 months. Costs were estimated from hospital patient administration system data. Outcomes: The primary outcome was glycosylated haemoglobin (HbA1c) concentration at 12 months. The secondary outcomes were (1) HbA1c concentrations of < 48 mmol/mol, (2) severe hypoglycaemia, (3) diabetic ketoacidosis (DKA), (4) T1D- or treatment-related adverse events (AEs), (5) change in body mass index and height standard deviation score, (6) insulin requirements, (7) QoL and (8) partial remission rate. The economic outcome was the incremental cost per quality-adjusted life-year (QALY) gained. Results: A total of 293 participants, with a median age of 9.8 years (minimum 0.7 years, maximum 16 years), were randomised (CSII, n = 149; MDI, n = 144) between May 2011 and January 2015. Primary outcome data were available for 97% of participants (CSII, n = 143; MDI, n = 142). At 12 months, age-adjusted least mean squares HbA1c concentrations were comparable between groups: CSII, 60.9 mmol/mol [95% confidence interval (CI) 58.5 to 63.3 mmol/mol]; MDI, 58.5 mmol/mol (95% CI 56.1 to 60.9 mmol/mol); and the difference of CSII – MDI, 2.4 mmol/mol (95% CI –0.4 to 5.3 mmol/mol). For HbA1c concentrations of < 48 mmol/mol (CSII, 22/143 participants; MDI, 29/142 participants), the relative risk was 0.75 (95% CI 0.46 to 1.25), and for partial remission rates (CSII, 21/86 participants; MDI, 21/64), the relative risk was 0.74 (95% CI 0.45 to 1.24). The incidences of severe hypoglycaemia (CSII, 6/144; MDI, 2/149 participants) and DKA (CSII, 2/144 participants; MDI, 0/149 participants) were low. In total, 68 AEs (14 serious) were reported during CSII treatment and 25 AEs (eight serious) were reported during MDI treatment. Growth outcomes did not differ. The reported insulin use was higher with CSII (mean difference 0.1 unit/kg/day, 95% CI 0.0 to 0.2 unit/kg/day; p = 0.01). QoL was slightly higher for those randomised to CSII. From a NHS perspective, CSII was more expensive than MDI mean total cost (£1863, 95% CI £1620 to £2137) with no additional QALY gains (–0.006 QALYs, 95% CI –0.031 to 0.018 QALYs). Limitations: Generalisability beyond 12 months is uncertain. Conclusions: No clinical benefit of CSII over MDI was identified. CSII is not a cost-effective treatment in patients representative of the study population. Future work: Longer-term follow-up is required to determine if clinical outcomes diverge after 1 year. A qualitative exploration of patient and professional experiences of MDI and CSII should be considered. Trial registration: Current Controlled Trials ISRCTN29255275 and EudraCT 2010-023792-25. Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 22, No. 42. See the NIHR Journals Library website for further project information. The cost of insulin pumps and consumables supplied by F. Hoffman-La Roche AG (Basel, Switzerland) for the purpose of the study were subject to a 25% discount on standard NHS costs.
- 1 August 2018
- Published by National Institute for Health and Care Research in Health Technology Assessment
- Vol. 22 (42) , 1-112
Continuous subcutaneous insulin infusion versus multiple daily injections in children and young people at diagnosis of type 1 diabetes: the SCIPI RCT
Background: The risk of developing long-term complications of type 1 diabetes (T1D) is related to glycaemic control and is reduced by the use of intensive insulin treatment regimens: multiple daily injections (MDI) (≥ 4) and continuous subcutaneous insulin infusion (CSII). Despite a lack of evidence that the more expensive treatment with CSII is superior to MDI, both treatments are used widely within the NHS. Objectives: (1) To compare glycaemic control during treatment with CSII and MDI and (2) to determine safety and cost-effectiveness of the treatment, and quality of life (QoL) of the patients. Design: A pragmatic, open-label randomised controlled trial with an internal pilot and 12-month follow-up with 1 : 1 web-based block randomisation stratified by age and centre. Setting: Fifteen diabetes clinics in hospitals in England and Wales. Participants: Patients aged 7 months to 15 years. Interventions: Continuous subsutaneous insulin infusion or MDI initiated within 14 days of diagnosis of T1D. Data sources: Data were collected at baseline and at 3, 6, 9 and 12 months using paper forms and were entered centrally. Data from glucometers and CSII were downloaded. The Health Utilities Index Mark 2 was completed at each visit and the Pediatric Quality of Life Inventory (PedsQL, diabetes module) was completed at 6 and 12 months. Costs were estimated from hospital patient administration system data. Outcomes: The primary outcome was glycosylated haemoglobin (HbA1c) concentration at 12 months. The secondary outcomes were (1) HbA1c concentrations of < 48 mmol/mol, (2) severe hypoglycaemia, (3) diabetic ketoacidosis (DKA), (4) T1D- or treatment-related adverse events (AEs), (5) change in body mass index and height standard deviation score, (6) insulin requirements, (7) QoL and (8) partial remission rate. The economic outcome was the incremental cost per quality-adjusted life-year (QALY) gained. Results: A total of 293 participants, with a median age of 9.8 years (minimum 0.7 years, maximum 16 years), were randomised (CSII, n = 149; MDI, n = 144) between May 2011 and January 2015. Primary outcome data were available for 97% of participants (CSII, n = 143; MDI, n = 142). At 12 months, age-adjusted least mean squares HbA1c concentrations were comparable between groups: CSII, 60.9 mmol/mol [95% confidence interval (CI) 58.5 to 63.3 mmol/mol]; MDI, 58.5 mmol/mol (95% CI 56.1 to 60.9 mmol/mol); and the difference of CSII – MDI, 2.4 mmol/mol (95% CI –0.4 to 5.3 mmol/mol). For HbA1c concentrations of < 48 mmol/mol (CSII, 22/143 participants; MDI, 29/142 participants), the relative risk was 0.75 (95% CI 0.46 to 1.25), and for partial remission rates (CSII, 21/86 participants; MDI, 21/64), the relative risk was 0.74 (95% CI 0.45 to 1.24). The incidences of severe hypoglycaemia (CSII, 6/144; MDI, 2/149 participants) and DKA (CSII, 2/144 participants; MDI, 0/149 participants) were low. In total, 68 AEs (14 serious) were reported during CSII treatment and 25 AEs (eight serious) were reported during MDI treatment. Growth outcomes did not differ. The reported insulin use was higher with CSII (mean difference 0.1 unit/kg/day, 95% CI 0.0 to 0.2 unit/kg/day; p = 0.01). QoL was slightly higher for those randomised to CSII. From a NHS perspective, CSII was more expensive than MDI mean total cost (£1863, 95% CI £1620 to £2137) with no additional QALY gains (–0.006 QALYs, 95% CI –0.031 to 0.018 QALYs). Limitations: Generalisability beyond 12 months is uncertain. Conclusions: No clinical benefit of CSII over MDI was identified. CSII is not a cost-effective treatment in patients representative of the study population. Future work: Longer-term follow-up is required to determine if clinical outcomes diverge after 1 year. A qualitative exploration of patient and professional experiences of MDI and CSII should be considered. Trial registration: Current Controlled Trials ISRCTN29255275 and EudraCT 2010-023792-25. Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 22, No. 42. See the NIHR Journals Library website for further project information. The cost of insulin pumps and consumables supplied by F. Hoffman-La Roche AG (Basel, Switzerland) for the purpose of the study were subject to a 25% discount on standard NHS costs.
- 1 April 2016
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 18 (4) , 213-215
What Matters for Calculating Insulin Bolus Dose?
- 1 April 2016
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 18 (4) , 213-215
What Matters for Calculating Insulin Bolus Dose?
- 27 February 2012
- Published by Springer Nature
- p. 73-99
Physical Activity in Childhood Diabetes